Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

132.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.0K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

16.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.9K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.1K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Membrane-Anchored and Sequence-Oriented Antiviral Activity of Fusion-Inhibitory Lipopeptides Derived from the SARS-CoV-2 Spike Glycoprotein S2 Subunit.

Viruses·2026
Same author

Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.

Chembiochem : a European journal of chemical biology·2026
Same author

Structure-Guided Design of Temporin-Derived Peptides Reveals Potent Dual-Mechanism Inhibitors of SARS-CoV-2.

Journal of medicinal chemistry·2026
Same author

Brick by Brick the Wall Is Being Built: Particle-Based Scaffolds for Regenerative Medicine.

Polymers·2025
Same author

Breastfeeding in a Polluted World: Perspective on the Properties of Breast Milk and the Need for Protection.

Journal of clinical medicine·2025
Same author

Comparison of Different Aliphatic Polyester-Based Microparticles as Protein Delivery Systems.

Polymers·2025

Related Experiment Video

Updated: Jan 30, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.9K

Modeling interaction between gp120 HIV protein and CCR5 receptor.

I Guryanov1, F Real-Fernández2, G Sabatino2,3

  • 1Institute of Chemistry, St. Petersburg State University, St. Petersburg, 198504, Russia.

Journal of Peptide Science : an Official Publication of the European Peptide Society
|January 26, 2019
PubMed
Summary
This summary is machine-generated.

Biomimetic nanotraps targeting HIV entry show promise. Nanoparticles with CCR5 receptor peptides and heparin effectively bind the HIV V3 loop, crucial for viral entry and potential therapeutic development.

Keywords:
CCR5HIVV3 loopchemokinegp120heparinnanoparticlepeptide

More Related Videos

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

9.1K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Related Experiment Videos

Last Updated: Jan 30, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.9K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

9.1K
Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions
06:01

Extracellular Protein Microarray Technology for High Throughput Detection of Low Affinity Receptor-Ligand Interactions

Published on: January 7, 2019

7.7K

Area of Science:

  • Biomedical Engineering
  • Virology
  • Materials Science

Background:

  • HIV entry into host cells is a critical target for diagnostics and therapeutics.
  • Biomimetic nanodevices offer a novel approach to intercept viral particles.
  • Previous work developed nanotraps targeting inflammatory chemokines via CCR5 receptor peptides.

Purpose of the Study:

  • To investigate the interaction of biomimetic nanotraps with the V3 loop of the HIV gp120 protein.
  • To evaluate the binding affinity of CCR5 receptor peptides (Nt and ECL2) to the V3 loop.
  • To determine the role of heparin and CCR5 peptides in nanotraps for V3 loop binding.

Main Methods:

  • Surface Plasmon Resonance (SPR) was used to measure binding kinetics and affinities.
  • Synthesis and characterization of multilayer nanoparticles (nanotraps) with heparin and CCR5 peptides.
  • Testing the binding of nanotraps and their peptide components to a V3 loop peptide.

Main Results:

  • A conformational rearrangement occurs during V3 loop and CCR5 fragment binding.
  • The ECL2 peptide exhibited higher affinity to the V3 peptide (KD = 3.72 × 10-8 M) than the Nt peptide (KD = 1.10 × 10-6 M).
  • Heparin-coated nanotraps functionalized with CCR5 peptides demonstrated effective binding to the V3 loop, with both components being essential.

Conclusions:

  • Short cationic peptides (ECL2 and Nt) derived from the CCR5 receptor are effective mimetics for V3 loop binding.
  • The developed nanotraps show potential for targeting HIV-1 entry.
  • Combined heparin and peptide functionalization is crucial for efficient V3 loop interaction.